#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

New antibiotics: do we need new molecules or new strategies?


Authors: Vladimír Krčméry 1,2;  Naďa Kulková 3
Authors‘ workplace: Slovenský tropický inštitút, VŠ zdravotníctva a sociálnej práce Sv. Alžbety, Bratislava, Slovenská republika, vedúci pracovník prof. MUDr. Vladimír Krčméry, Dr. Sc., FRCP, FACP. 1;  Mikrobiologický ústav LF UK a UN Bratislava, Slovenská republika, vedúci prof. MUDr. Vladimír Krčméry, DrSc., FRCP, FACP 2;  Laboratórium molekulárnej mikrobiológie - spoločné výskumné pracovisko FZaSP TU a VŠ ZaSP sv. Alžbety, Bratislava, Slovenská republika, vedúci prof. MUDr. Vladimír Krčméry, Dr. Sc., FRCP, FACP 3
Published in: Vnitř Lék 2014; 60(Suppl 2): 40-45
Category: 70th Birthday - prof. MUDr. Jiří Vorlíček, CSc.

Overview

Even though the situation in the field of research and development of new antimicrobial agents is not ideal, the years of stagnation, especially among anti-gramnegative agents, seem to be over. During the years 2011–2012 we have witnessed a movement towards a development of some new antibiotic agents not only with anti-gramposi­tive activity but with anti-gramnegative too, as well as new antituberculotics and antifungals. Here we present some of these new antiinfectives, presented in conferences during the last year, of which many are being shifted to the level of clinical trials of phase II–III, while others are in stage of preclinical studies.

Keywords:
antibiotics – antimycotics – antituberculotics


Sources

1. Aktaş Z, Kayacan C, Oncul O. In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae. Int J Antimicrob Agents 2012; 39(1): 86–89.

2. Andries K. Bedaquiline (TMC207), a first-in-class drug candidate for MDR TB. In Abstracts of the 22nd European Congress of Clinical Microbiology and Infectious Diseases. London, United Kingdom. March 31-April 3, 2012. Clin Microbiol Infect 2012; 18(Suppl 3): 1–902.

3. Andries K, Verhasselt P, Guillemont J et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005; 307(5707): 223–227.

4. Baldoni D, Gutierrez M, Dingemanse J et al. Cadazolid, a Novel Antibiotic with Potent Activity against Clostridium difficile: Safety, Tolerability, and Pharmacokinetics in Healthy Subjects following Single and Multiple Oral Doses. In American Society of Microbiology (Ed). 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy 2012. Omnipress: Washington DC.

5. Deane J, Simenauer A, Ge Y et al. In Vitro Activity of KPI-10 Against Clinically Important Gram- Negative Bacteria. In A. S. for Microbiology (Ed). 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy 2012. Omnipress: Washington DC.

6. Diacon AH, Dawson R, von Groote-Bidlingmaier F et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet 2012; 380(9846): 986–993.

7. Dooley K, Park J Jr, Swindells S et al. A Phase I, Safety, Tolerability, and Pharmacokinetic Interaction of Single-Dose TMC207 and Efavirenz in Healthy Volunteers. 4th International Workshop on Clinical Parmacology of TB Drugs. Chicago: AIDS Clinical Trials Group 2011.

8. Hashizume H, Sawa R, Harada S et al. Tripropeptin C blocks the lipid cycle of cell wall biosynthesis by complex formation with undecaprenyl pyrophosphate. Antimicrob Agents Chemother 2011; 55(8): 3821–3828.

9. Heim J, Roussel P, Milligan D et al. Ev-035 : Novel 2-pyridone Based Topoisomerase Inhibitors with Broad-spectrum Activity Against MDR Pathogens Including Quinolone Resistance. In American Society for Microbiology (Ed), 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy 2012. Omnipress: Washington DC.

10. Hirosawa S, Hashizume H, Kobayashi Y et al. In Vitro Antimicrobial Activity and in vivo Efficacy in a Mouse Staphylococcal-Septicemia Model of Water-soluble Tripropeptin C Analogs. In A. S. for Microbiology (Ed). 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy 2012. Omnipress: Washington DC.

11. Huang E, Guo Y, Yousef A Antimicrobial Spectrum and Biosynthesis of the New Lipopeptide Antibiotic, Paenibacterin. In A. S. for Microbiology (Ed). 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy 2012. Omnipress: Washington DC.

12. Janssen Therapeutics Sirturo: Prescribing information. Janssen Therapeutics, Division of Janssen Products, LP Titusville, NJ 08560, Janssen Products, LP 2012.

13. Lepak AJ, Marchillo K, Pichereau S et al. Comparative pharmacodynamics of the new oxazolidinone tedizolid phosphate and linezolid in a neutropenic murine Staphylococcus aureus pneumonia model. Antimicrob Agents Chemother 2012; 56(11): 5916–5922.

14. Lomovskaya O, King P, Sun D et al. Microbiological Characterization of Beta-Lactamase Inhibitor RPX7009. In A. S. of Microbiology (Ed). 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy 2012. Omnipress: Washington DC.

15. Maki H, Nakai H, Hori T et al. COT-303 , A Novel Glycosylated Glycopeptide : I. In vitro Activity Against Gram-positive Bacteria. In A. S. for Microbiology (Ed). 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy 2012. Omnipress: Washington DC.

16. Miesel L, Baysarowich J, Caron A et al. M676 , a Putative Inhibitor of Undecaprenyl Pyrophosphate Synthase , Synergizes with β-lactam Antibiotics Against MRSA. In American Society for Microbiology (Ed). 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy 2012. Washington DC: Omnipress.

17. Miller B, Hershberger E, Benziger D et al. Pharmacokinetics and safety of intravenous ceftolozane-tazobactam in healthy adult subjects following single and multiple ascending doses. Antimicrob Agents Chemother2012; 56(6): 3086–3091.

18. Mitsuyama J, Nomura N, Hashimoto K et al. In vitro and in vivo antifungal activities of T-2307, a novel arylamidine. Antimicrob Agents Chemother 2008; 52(4): 1318–1324.

19. Morikawa H, Okada A, Tomishima M et al. ASP9726, A Unique 2nd Generation Echinocandin (2) – Synthesis and In Vitro Activity. In A. S. for Microbiology (Ed). 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy 2012. Omnipress: Washington DC.

20. Naderer O, Jones L, Zhu J et al. A-1276 Intravenous (IV) First Time in Human Safety and Pharmacokinetics of GSK1322322 (GSK322), a Peptide Deformylase Inhibitor Antibacterial. In American Society for Microbiology (Ed). 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy 2012. Omnipress: Washington DC.

21. Page MGP, Dantier C, Desarbre E. In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli. Antimicrob Agents Chemother 2010; 54(6): 2291–2302.

22. Patel D, Patel R, Kumari P et al. Microwave-assisted synthesis of coumarin based 1,3,5-triazinyl piperazines and piperidines and their antimicrobial activities. Acta Pol Pharm 2012; 69(5): 879–991.

23. Pereira D, Li J, Fernandes P et al. Pikromycin Derivative of Solithromycin : Discussion of Activity. In American Society for Microbiology (Ed). 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy 2012. Omnipress: Washington DC.

24. Prokocimer P, Bien P, Deanda C et al. In vitro activity and microbiological efficacy of tedizolid (TR-700) against Gram-positive clinical isolates from a phase 2 study of oral tedizolid phosphate (TR-701) in patients with complicated skin and skin structure infections. Antimicrob Agents Chemother 2012; 56(9): 4608–4613.

25. Reck F, Alm RA, Brassil P et al. Novel N-linked aminopiperidine inhibitors of bacterial topoisomerase type II with reduced pK(a): antibacterial agents with an improved safety profile. J Med Chem 2012; 55(15): 6916–6933.

26. Riccobene TA, Su SF, Rank D A single- and multiple-dose study to determine the safety, tolerability, and pharmacokinetics of ceftaroline fosamil in combination with avibactam in healthy subjects. Antimicrob Agents Chemother. 2013; 57(3): 1496–1504.

27. Rodgers W, Frazier AD, Champney WS. Solithromycin Inhibition of Protein Synthesis and Ribosome Biogenesis in Staphylococus aureus, Streptococcus pneumoniae, and Haemophilus influenzae. Antimicrob Agents Chemother 2013; 57(4):1632–1637.

28. Rubinstein E. New antibiotics 2012. Abstract & Poster Book – 3rd Southeast European Conference on Chemotherapy and Infection. In SEEC (Ed). 3rd Southeast European Conference on Chemotherapy and Infection 2012. Dubrovnik, Croatia.

29. Sharma S, Gupta A, Arora A. Cefepime Tazobactam: A new β lactam/ β lactamase inhibitor combination against ESBL producing gram negative bacill. Int J Pharm Biomed Sci 2012, 3(2), 35–38.

30. Shibata T, Takahashi T, Yamada E et al. T-2307 causes collapse of mitochondrial membrane potential in yeast. Antimicrob Agents Chemother 2012; 56(11): 5892–5897.

31. Shoham M, Yu G, Truitt B et al. Antivirulence Agents Against MRSA and Streptococcus pyogenes. In American Society for Microbiology (Ed). 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy 2012. Omnipress: Washington DC.

32. Upton AM TBA-354: A Next generatioin nitroimidazole for treatment of drug sensitive and drug resistant tuberculosis. In A. S. for Microbiology (Ed). 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy 2012. Omnipress: Washington DC.

33. Vivien E, Pitorre D, Cociancich S et al. Heterologous production of albicidin: a promising approach to overproducing and characterizing this potent inhibitor of DNA gyrase. Antimicrob Agents Chemother 2007; 51(4): 1549–1552.

34. Zhanel GG, Calic D, Schweizer F et al. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin. Drugs 2010; 70(7): 859–886.

35. Zhanel GG, Lawson CD, Zelenitsky S et al. Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin. Expert Rev Anti Infect Ther 2012; 10(4): 459–473.

36. Zhang S, Mortin L, Chuong C et al. In vivo Efficacy of CB-027 against Methicillin-Resistant Staphylococcus aureus, and Ceftazidime-Resistant Infections in Mice. In A. S. of Microbiology (Ed). 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy 2012. Omnipress: Washington DC.

37. Zhu D, Kurosaka Y, Hoshino K DS-8587, A New Generation of Broad Spectrum Quinolone : In Vitro Antibacterial Activities Against Chinese Clinical Isolates. In A. S. for Microbiology (Ed). 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy 2012. Omnipress: Washington DC.

38. Zhu DM, Wang W, Huang Y et al. Antibacterial spectrum of oxazolidinone MRX-I: Potent activity against multidrug-resistant Gram-positive pathogens. In American Society for Microbiology (Ed). 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 2012. Omnipress: Washington DC.

Labels
Diabetology Endocrinology Internal medicine
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#